Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway

Li, Dezhi; Hu, Xingsheng; Yu, Sijia; Deng, Shumin; Yan, Min; Sun, Fengfei; Jun-mei, Song; Tang, Lina

doi:10.1016/j.cellsig.2020.109697

Cited by 31 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results demonstrate that the effects of DLG3 in OSCC are obtained via the Hippo signaling pathway. Recent data suggested that DLG3 is capable of binding to MST2 and then regulating LAST1, thus reducing translocation of YAP protein into nuclei (16). Furthermore, another study has revealed increased cell proliferation and decreased cell apoptosis when the Hippo signaling pathway is inactivated (38).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, DLG3 exhibits low expression in several cancers, including colon cancer, glioblastoma and lung cancer (15). A recent study has demonstrated that up-regulated DLG3 activated the Hippo signaling pathway, thereby suppressing breast cancer cell proliferation and promoting their apoptosis (16). The Hippo signaling pathway plays a crucial role in tissue development and homeostasis, acting in multiple cancer types via its core components, which include mammalian sterile 20-like 1/2 (MST1/2), large tumor suppressor 1/2 (LATS1/2), and Yes kinase-associated protein (YAP) (17).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED: LINC01315 Impairs microRNA-211-Dependent DLG3 Downregulation to Inhibit the Development of Oral Squamous Cell Carcinoma

Chen

Zhou

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Recent studies have revealed that long non-coding RNAs (lncRNAs) involve in the progression of oral squamous cell carcinoma (OSCC). These lncRNAs have emerged as biomarkers or therapeutic targets for OSCC. We here aimed to investigate the role of lncRNA LINC01315 in OSCC and the related mechanisms. LINC01315 and DLG3 were determined to be poorly expressed while microRNA-211 (miR-211) was highly expressed in OSCC tissues and cells using RT-qPCR and western blot analysis. Based on the results obtained from dual-luciferase reporter gene, RIP, and FISH assays, LINC01315 was found to upregulate DLG3 expression by competitively binding to miR-211. Upon altering the expression of LINC01315, and/or miR-211 in OSCC cells with shRNA, mimic, or an inhibitor, we assessed their effects on OSCC cell proliferation, migration, invasion, and apoptosis. LINC01315 knockdown enhanced OSCC cell proliferation, migration and invasion, but dampened their apoptosis, all of which could be reversed by miR-211 inhibition. Elevation of DLG3, a target gene of miR-211, activated the Hippo signaling pathway, whereby suppressing OSCC progression in vitro. Finally, their roles in tumor growth were validated in vivo. These findings suggest that LINC01315 elevates DLG3 expression by competitively binding to miR-211, thereby suppressing OSCC progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

RETRACTED: LINC01315 Impairs microRNA-211-Dependent DLG3 Downregulation to Inhibit the Development of Oral Squamous Cell Carcinoma

Chen

Zhou

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Up-regulation of MIAT has been found in breast cancer cell lines and breast tumor samples compared to the normal breast tissue [ 34 , 35 , 36 ]. Li et al (2020) evaluated the expression of MIAT breast cancer cases and found that its expression was associated with poor prognosis [ 37 ]. They also provided experimental evidence for the mechanism by which MIAT influences the progression of BRCA, showing that MIAT overexpressed in breast cancer cells promotes invasion, migration, and DLG3 promoter methylation.…”

Section: Discussionmentioning

confidence: 99%

Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer

Pavanelli

Mangone

Barros

et al. 2021

Genes

View full text Add to dashboard Cite

Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients’ prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients’ prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan–Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.

show abstract

“…In breast cancer, lncRNA MIAT combines with DNMT1, DNMT3A, and DNMT3B. In migratory, invasive breast cancer, MIAT/DNMT1/DNMT3A/DNMT3B complexes suppress the HIPPO signaling pathway by downregulating discs large MAGUK scaffold protein 3 (DLG3) transcription level via recruitment to the DLG3 promoter region, and it thereby increases the translocation of yes-associated protein 1 (YAP) into the nucleus [ 62 ]. Highly expressed lncRNA CCAT1 also binds to Annexin A2 (ANXA2) and glycogen synthase kinase 3 beta (GSK3β), which leads to the nuclear translocation of β-catenin.…”

Section: Lncrna–protein Interaction In Cancer Developmentmentioning

confidence: 99%

Epigenetic Mechanisms of LncRNAs Binding to Protein in Carcinogenesis

Shin

Lee

Cho

2020

Cancers

View full text Add to dashboard Cite

Epigenetic dysregulation is an important feature for cancer initiation and progression. Long non-coding RNAs (lncRNAs) are transcripts that stably present as RNA forms with no translated protein and have lengths larger than 200 nucleotides. LncRNA can epigenetically regulate either oncogenes or tumor suppressor genes. Nowadays, the combined research of lncRNA plus protein analysis is gaining more attention. LncRNA controls gene expression directly by binding to transcription factors of target genes and indirectly by complexing with other proteins to bind to target proteins and cause protein degradation, reduced protein stability, or interference with the binding of other proteins. Various studies have indicated that lncRNA contributes to cancer development by modulating genes epigenetically and studies have been done to determine which proteins are combined with lncRNA and contribute to cancer development. In this review, we look in depth at the epigenetic regulatory function of lncRNAs that are capable of complexing with other proteins in cancer development.

show abstract

Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway

Cited by 31 publications

References 32 publications

RETRACTED: LINC01315 Impairs microRNA-211-Dependent DLG3 Downregulation to Inhibit the Development of Oral Squamous Cell Carcinoma

RETRACTED: LINC01315 Impairs microRNA-211-Dependent DLG3 Downregulation to Inhibit the Development of Oral Squamous Cell Carcinoma

Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer

Epigenetic Mechanisms of LncRNAs Binding to Protein in Carcinogenesis

Contact Info

Product

Resources

About